Chemoimmunotherapy in Non-Hodgkin's Lymphoma CHOP vs. CHOP + Levamisole + BCG for Remission Induction: Levamisole vs. No Maintenance After Remission Induction

Racial disparities in survival of patients with sex-specific cancers treated on Southwest Oncology Group clinical trials. PMC2724852; PMID: 19584328

KS Albain;JM Unger;JJ Crowley;CA Coltman;DL Hershman Journal of the National Cancer Institute 101(14):984-992

Minority report: how best to analyze clinical trial data to address disparities

D Hershman;J Unger Breast Cancer Research and Treatment 118:519-521

Non-hodgkins lymphoma

R Fisher;P Mauch;J Friedberg;L Rimsza In Cancer: Principles and Practice of Oncology, 8th edition, Lippincott, Williams & Wilkins, Baltimore, MD, pp 2098-2158, 2008

New treatment options have changed the survival of patients with follicular lymphoma

RI Fisher;M LeBlanc;OW Press;DG Maloney;JM Unger;TP Miller Journal of Clinical Oncology 23(33):8447-8452

New REAL clinical entities.

RI Fisher;TP Miller;TM Grogan Cancer Journal from Scientific American 4(Suppl.2):S5-S12

Follicular lymphomas: Do histologic subtypes predict outcome?

TP Miller;M LeBlanc;TM Grogan;RI Fisher Hematology/Oncology Clinics of North America 11(5):893-900

Evaluation and management of mantle cell lymphoma.

OW Press;TM Grogan;RI Fisher Advances in Leukemia and Lymphoma 6(1):3-11

Clinical course and therapy of mantle cell lymphoma.

RI Fisher;OW Press;TP Miller;DR Head Principles and Practice of Oncology 10(6):1-7

Mantle-cell lymphoma: Classification and therapeutic implications.

RI Fisher Annals of Oncology 7(Suppl.6):S35-S39

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

BW Dana;S Dahlberg;BN Nathwani;E Chase;C Coltman;TP Miller;RI Fisher Classic Papers and Current Comments 1(2):320-328

A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid b-cell subcategories: A Southwest Oncology Group study.

RI Fisher;S Dahlberg;BN Nathwani;PM Banks;TP Miller;TM Grogan Blood 85(4):1075-1082

A clinical analysis of new indolent lymphoma entities in the revised european american lymphoma (REAL) classification.

RI Fisher;S Dahlberg;TM Grogan ASCO 13:379(#1287)

Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.

BW Dana;S Dahlberg;BN Nathwani;E Chase;CA Coltman Jr;TP Miller;RI Fisher JCO 11(4):644-651

Treatment of diffuse large-cell lymphoma: A summary of outcome for patients treated by the Southwest Oncology Group.

TP Miller;S Dahlberg Malignant Lymphomas Including Hodgkins Disease 4:53-63

Long-term followup of patients with low grade lymphoma treated with CHOP ( cyclophosphamide, doxorubicin, vincristine, prednisone)-based chemotherapy or chemoimmunotherapy on Southwest Oncology Group studies

B Dana;S Dahlberg;T Miller;S Jones;E Chase;C Coltman, Jr;R Fisher ASCO 8:257(#1001)

Long-term survival of patients with nodular histiocytic (NH),diffuse poorly differentiated lymphocytic (DPDL), diffuse mixed (DM),and diffuse undifferentiated (DU) lymphoma treated with CHOP chemotherapy.

RI Fisher;S Dahlberg;TP Miller;SE Jones;C Coltman, Jr ASCO 8:257(#1003)

Mitotic counts in follicular lymphomas.

DJ Ellison;BN Nathwani;GE Metter;RR Turner;JS Burke;TP Miller;RB Mann;M Barcos;CR Kjeldsberg;CD Winberg;CC Whitcomb Human Pathology 18:502-505

Effect of age on therapeutic outcome in advanced diffusehistiocytic lymphoma: the Southwest Oncology Group experience.

DO Dixon;BA Neilan;SE Jones;DA Lipschitz;TP Miller;SE Salmon;PN Grozea;SP Balcerzak JCO 4(3):296-305

What should be the morphologic criteria for the subdivision offollicular lymphomas?

BN Nathwani;GE Metter;TP Miller;JS Burke;RB Mann;M Barcos;CR Kjeldsberg;DO Dixon;CD Winberg;CC Whitcomb;SE Jones Blood 68(4):837-845

CHOP is curative in thirty percent of patients with diffuse largecell lymphoma: A twelve year Southwest Oncology Group followup.

C Coltman, Jr;S Dahlberg;SE Jones;TP Miller;BW Dana;EM McKelvey;RJ Hartsock;DO Dixon ASCO 5:197(#774)

Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole plus BCG for malignant lymphoma: a Southwest Oncology Group study.

SE Jones;PN Grozea;TP Miller;EJ Van Slyck;SP Balcerzak;JJ Costanzi;FS Morrison;HJ Eyre;CJ Fabian;L Dabich;DO Dixon;RJ Hartsock;TM Grogan;C Kjeldsberg;B Schnitzer JCO 3(10):1318-1324

Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for lymphoma clinical studies.

GE Metter;BN Nathwani;JS Burke;CD Winberg;RB Mann;M Barcos;CR Kjeldsberg;CC Whitcomb;DO Dixon;TP Miller;SE Jones JCO 3(1):25-38

Chemotherapy with cyclophosphamide, Adriamycin, vincristine, and prednisone (CHOP) alone or with levamisole or levamisole plus BCG for non-Hodgkin's lymphoma (NHL): A Southwest Oncology Group study

S Jones;P Grozea;R O'Bryan;S Balcerzak;J Costanzi;J Athens;C Fabian;L Dabich;D Dixon ASCO #C-927

Prevention of central nervous system relapse in unfavorable histology non-Hodgkin's lymphoma. A Southwest Oncology Group study

KL Fielder;SE Jones;DO Dixon;PN Grozea;RM O'Bryan;JJ Costanzi;SP Balcerzak American Society of Hematology poster presentation, December

Prevention of CNS relapse in unfavorable histology non-Hodgkin's lymphoma

KL Fielder;SE Jones;DO Dixon;PN Grozea;RM O'Bryan;JJ Costanzi;SP Balcerzak Blood 62 (Suppl 1):212a (753)

The chemotherapy of lymphoblastic lymphoma

JB Voakes;SE Jones;EM McKelvey Blood 57:186-188

Chemoimmunotherapy versus chemotherapy for remission induction in patients with non-Hodgkin's lymphoma: Progress report of a Southwest Oncology Group study

SE Jones Recent Results Cancer Res 65:164-169, 1978